These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28472743)

  • 1. Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.
    Pastorino U; Morelli D; Leuzzi G; Gisabella M; Suatoni P; Taverna F; Bertocchi E; Boeri M; Sozzi G; Cantarutti A; Corrao G
    Eur J Cancer; 2017 Jul; 79():90-97. PubMed ID: 28472743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy.
    Pastorino U; Morelli D; Leuzzi G; Rolli L; Suatoni P; Taverna F; Bertocchi E; Boeri M; Sozzi G; Cantarutti A; Corrao G; Gronchi A
    Ann Surg Oncol; 2019 Mar; 26(3):869-875. PubMed ID: 30607764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
    Shinohara S; Sugaya M; Onitsuka T; Machida K; Matsuo M; Tanaka F
    Anticancer Res; 2018 May; 38(5):3193-3198. PubMed ID: 29715162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory status and lung function predict mortality in lung cancer screening participants.
    Pastorino U; Morelli D; Marchianò A; Sestini S; Suatoni P; Taverna F; Boeri M; Sozzi G; Cantarutti A; Corrao G
    Eur J Cancer Prev; 2018 Jul; 27(4):289-295. PubMed ID: 28333763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index, C-reactive protein and survival in smokers undergoing lobectomy for lung cancer†.
    Nagata M; Ito H; Matsuzaki T; Furumoto H; Isaka T; Nishii T; Yokose T; Nakayama H
    Eur J Cardiothorac Surg; 2017 Jun; 51(6):1164-1170. PubMed ID: 28199511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer.
    Alifano M; Falcoz PE; Seegers V; Roche N; Schussler O; Younes M; Antonacci F; Forgez P; Dechartres A; Massard G; Damotte D; Régnard JF
    J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1161-7. PubMed ID: 21872279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lopez-Pastorini A; Riedel R; Koryllos A; Beckers F; Ludwig C; Stoelben E
    Lung Cancer; 2017 Jul; 109():68-73. PubMed ID: 28577953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].
    Shen L; Li ZM; Lu S
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):442-6. PubMed ID: 21875485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of C-Reactive Protein as a Prognostic Marker in Advanced Cancer Patients in Palliative Care Settings.
    Amano K; Maeda I; Morita T; Miura T; Inoue S; Ikenaga M; Matsumoto Y; Baba M; Sekine R; Yamaguchi T; Hirohashi T; Tajima T; Tatara R; Watanabe H; Otani H; Takigawa C; Matsuda Y; Nagaoka H; Mori M; Kinoshita H
    J Pain Symptom Manage; 2016 May; 51(5):860-7. PubMed ID: 26826676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
    Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
    Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein levels and cancer mortality.
    Ko YJ; Kwon YM; Kim KH; Choi HC; Chun SH; Yoon HJ; Goh E; Cho B; Park M
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2076-86. PubMed ID: 23136255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors.
    Voltolini L; Bongiolatti S; Luzzi L; Bargagli E; Fossi A; Ghiribelli C; Rottoli P; Gotti G
    Eur J Cardiothorac Surg; 2013 Jan; 43(1):e17-23. PubMed ID: 23129356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
    Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
    Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and endovascular treatment of lower limb peripheral artery disease: an independent prognostic factor.
    Bleda S; de Haro J; Varela C; Acin F
    J Endovasc Ther; 2015 Apr; 22(2):233-9. PubMed ID: 25809368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
    Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
    Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
    Bedke J; Chun FK; Merseburger A; Scharpf M; Kasprzyk K; Schilling D; Sievert KD; Stenzl A; Kruck S
    BJU Int; 2012 Dec; 110(11 Pt B):E771-7. PubMed ID: 23134582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year mortality in cardiac surgery patients with low cardiac output syndrome treated with levosimendan: prognostic evaluation of NT-proBNP and C-reactive protein.
    Torrado H; Lopez-Delgado JC; Farrero E; Rodríguez-Castro D; Castro MJ; Periche E; Carriò ML; Toscano JE; Pinseau A; Javierre C; Ventura JL
    Minerva Cardioangiol; 2016 Apr; 64(2):101-13. PubMed ID: 26977768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.